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Abstract
Objective
To investigate the eﬀects of natalizumab (NAT) treatment on intrathecally produced antiviral
antibodies in MS.
Methods
We performed a longitudinal, observational study analyzing both serum and CSF samples
collected before and during NAT treatment for antibodies against measles, rubella, mumps,
inﬂuenza, entero, herpes, and polyoma viruses, including JC polyomavirus (JCV) and its
nearest homologue BK polyomavirus (BKV), and bacterial control antigens by ELISA to
determine the antigen-speciﬁc CSF antibody index (CAI). CAI ≥1.5 indicated intrathecal
synthesis of antigen-speciﬁc antibodies. Oligoclonal bands (OCBs) by isoelectric focusing and
total IgG, IgM, and IgA by immunonephelometry were analyzed additionally.
Results
Intrathecal synthesis of JCV- and BKV-speciﬁc IgG was detected in 20% of patients with MS at
baseline and was lost signiﬁcantly more frequently during NAT treatment compared with other
intrathecal antiviral and antibacterial antibody reactivities. Peripheral JCV- and BKV-speciﬁc
antibody responses persisted, and no cross-reactivity between JCV- and BKV-speciﬁc CSF
antibodies was found. Intrathecal production of antibodies against measles, rubella, and zoster
antigens (MRZ reaction) was most prevalent and persisted (73.3% before vs 66.7% after 1 year
of NAT therapy). CSFOCBs also persisted (93.3% vs 80.0%), but total CSF IgG and IgM levels
declined signiﬁcantly.
Conclusions
These data indicate that JCV-speciﬁc antibodies are produced intrathecally in a minority of
patients with MS, and NAT treatment aﬀects the intrathecal humoral immune response against
JCV relatively speciﬁcally compared with other neurotropic viruses. Further studies are needed
to determine whether this eﬀect translates to higher risk of progressive multifocal leukoence-
phalopathy development.
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Natalizumab (NAT) is a highly eﬃcacious treatment for
relapsing-remitting MS (RRMS) and hinders immune cells
from entry into the CNS. However, this also compromises
physiologic CNS immune surveillance and is an important
reason for NAT-associated progressive multifocal leu-
koencephalopathy (NAT-PML). PML is an opportunistic
CNS infection with JC polyomavirus (JCV) and has emerged
as a serious adverse event in 778 NAT-treated patients
worldwide (incidence of 4.2/1,000) with fatal outcome in
23% of cases,1,2 whereas other CNS infections occur far less
frequently (incidence of herpes virus CNS infections at 0.2/
1,000).3 Why NAT-treated patients are more prone to de-
velop PML than other viral CNS infections is not clear.4
NAT impairs entry of B and plasma cells into the CNS and is
associated with decreased total CSF IgG and IgM levels.5–7
Moreover, NAT may reduce the prevalence, number, and/or
intensity of CSF oligoclonal bands (OCBs),7–9 whereas the
inﬂuence on polyspeciﬁc intrathecal antibody reactivity to
measles, rubella, and zoster (MRZ reaction) remains less ex-
amined.7 Positive OCBs and MRZ reaction in CSF are com-
mon, well established, and stable surrogates of ongoing
intrathecal humoral immune reaction in MS.10,11 Intrathecal
production of JCV-speciﬁc antibodies has been described in
3.6% of patients with MS12 and thus may be part of the “pol-
yspeciﬁc” CSF humoral immune reaction, which is usually
depicted by the MRZ reaction, but which extends to many
other viruses.12–15 Of interest, JCV-speciﬁc CSF antibody
production was not found in NAT-treated patients with MS,
but in 55% of patients with NAT-PML,16 indicating that it is an
important aspect of protective immune responses against PML.
Here, we addressed how NAT inﬂuences the spectrum of
intrathecally produced antibodies against various pathogens
including JCV.
Methods
Patients and samples
Paired serum and CSF samples were collected from 15
patients (male/female ratio 1:4; mean age 40.13 years [range
18–53 years]) diagnosed with RRMS according to 2005 re-
vised McDonald criteria17 at the University Medical Center
Hamburg-Eppendorf, Hamburg, Germany, before NAT (V0),
and after 12 months (V12) and 24 months (V24, only from
6 patients, loss of follow-up in 9 patients due to denial of
further participation) of NAT treatment (300 mg IV every 4
weeks). The patients had not received steroids 4 weeks before
NAT treatment or any immunomodulatory or immunosup-
pressive agent 3 months before NAT treatment. Additional 25
serum samples fromhealthy donors were used for determining
the cutoﬀ value (COV) of seropositivity in JCV ELISA.
Standard protocol approvals, registrations,
and patient consents
The local ethics committee (Ethik-Kommission der
A¨rztekammer Hamburg, Germany, protocol No. 2758) ap-
proved the study. All patients gave written informed consent.
Antibody detection in serum and CSF
Antibody reactivity against the following viral lysates and
bacterial antigens was tested using commercial ELISA kits
from Euroimmun (Lu¨beck, Germany): measles, rubella,
mumps, herpes simplex virus type 1/2 (HSV-1/HSV-2), cy-
tomegalovirus (CMV), varicella zoster virus (VZV), inﬂuenza
virus A and B (inﬂuenza A and B), and enterovirus lysates;
Epstein-Barr virus (EBV) nuclear antigen-1 (EBNA-1) and
EBV viral capsid antigen (EBV-VCA); and tetanus toxoid
(tetanus), diphtheria toxoid (diphtheria), Helicobacter pylori,
and Chlamydophila pneumoniae antigens. Antipolyomaviral
IgG reactivity was determined using BK polyomavirus (BKV)-,
KI polyomavirus (KIV)-, or WU polyomavirus (WUV)-viral
protein 1 (VP1) fused to glutathione S-transferase (kind gift
from Robert L. Garcea, Boulder, CO) or JCV-VP1 (MAD1
strain, Life Science Incubator, Bonn, Germany), as described
previously.18,19 Brieﬂy, ELISA plates were coated with 200 ng
of the respective polyomavirus-VP1/well and incubated with
serum (1:400, 1:2,020 dilutions) and CSF (1:2, 1:10, 1:100,
and 1:1,000 dilutions). Human IgG was detected using biotin-
conjugated anti-human mouse Fc antibody and avidin horse-
radish peroxidase (eBioscience, Frankfurt, Germany). Optical
density at 450 nm (OD450) was assessed using a Synergy H1
reader (BioTek, Luzern, Switzerland). Antibody reactivity was
assessed in arbitrary units (AUs) using a standard curve
obtained from a serial dilution of the respective standard serum
for interpolating ODs by 4 parameter logistic curve ﬁt. AUs
within the linear part of the standard curve were multiplied by
the corresponding dilution factor to obtain absolute AU.
Highly reactive samples exceeding the linear limits of the
standard curve were further diluted.
The antigen-speciﬁc CSF/serum antibody index (CAIspec) was
calculated according to Reiber.20 Brieﬂy, CAIspec was assessed
as CAIspec = Qspec/QIgG, if QLim > QIgG, or CAI = Qspec/QLim
(IgG), if QLim < QIgG. The variables were calculated as follows:
Qspec = antigen-speciﬁc IgGCSF [AU]/antigen-speciﬁc IgGserum
Glossary
AU = arbitrary unit; BBB = blood-brain barrier; CAI = CSF antibody index; CMV = cytomegalovirus; COV = cutoﬀ value;
EBV = Epstein-Barr virus; EBNA-1 = EBV nuclear antigen-1; EBV-VCA = EBV viral capsid antigen; HSV = herpes simplex
virus; JCV = JC polyomavirus;MRZ reaction = measles, rubella, and zoster antigens; NAT = natalizumab;OCB = oligoclonal
band; OD = optical density; PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting MS; VZV =
varicella zoster virus.
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[AU]; Q IgG = IgGCSF/IgGserum; QLim (IgG) = 0.93× (Qalb
2
+ 6 × 10−6)0.5 − 1.7 × 10−3; Qalb = albCSF/albserum (with alb =
albumin). QLim (IgG) refers to the upper discrimination line
of the hyperbolic reference range for the blood-derived IgG
in CSF as 0 intrathecal IgG synthesis. Intrathecal antigen-
speciﬁc antibody synthesis was deﬁned as CAIspec ≥ 1.5.
Serum and CSF samples were preincubated with BKV before
testing with JCV ELISA and vice versa to assess JCV/BKV
cross-reactivity. For the determination of the COV of JCV,
BKV, KIV, and WUV seropositivity, we measured sera from
the above-mentioned patients with MS and additional 25
healthy donors (among them seropositive and negative
donors) using antigen-speciﬁc ELISA. Normalized ODs
were calculated by subtracting the mean OD of negative
controls and divided by the OD of 1/500 diluted standard
serum. We determined the COV of antigen-speciﬁc sero-
positivity by ranking normalized ODs and calculating the
inﬂection point.
Albumin and total IgG, IgM, and IgA in serum and CSF were
quantiﬁed by immunonephelometry (Unilabs, Zurich, Swit-
zerland). IgG index was calculated as IgG index = QIgG/Qalb
(for QIgG and Qalb see above) and IgM index and IgA index
each accordingly. IgG index ≥0.7 indicated intrathecal syn-
thesis of IgG. The relative intrathecal fraction of IgM and IgA,
respectively (IgMIF and IgAIF), were calculated according to
Reiber.20 IgMIF ≥ 10% and IgAIF ≥ 10% indicated signiﬁcant
intrathecal synthesis of IgM and IgA, respectively. OCBs were
detected by isoelectric focusing on polyacrylamide gels and
immunoblotting using IgG-speciﬁc antibodies (Serva, Ger-
many, Heidelberg, Germany). OCBs were considered posi-
tive in case of ≥2 additional bands.
Statistical analysis
Prism v5.0 (GraphPad software, San Diego, CA) was used for
statistical analysis. The McNemar test (for dichotomous
measures) and Wilcoxon-matched pairs test (for quantitative
measures) were used to compare between V0 and V12. To
test whether the frequency of loss of intrathecal antibody
synthesis speciﬁc for a given antigen between V0 and V12 is
the same as the frequency of loss of intrathecal antibody
synthesis speciﬁc for all other antigens between V0 and V12,
we used the Fisher exact test. All the 20 antigens tested and
recognized by intrathecally produced antibodies were regar-
ded as a priori independent of each other. The primary aim
was to compare whether loss of intrathecal JCV-speciﬁc an-
tibody synthesis between V0 and V12 was signiﬁcantly more
frequent than the loss of intrathecal antibody synthesis spe-
ciﬁc for all antigens other than JCV. Probability values of p <
0.05 were considered signiﬁcant in the primary aim. A second,
exploratory aim was to compare the frequency of loss of in-
trathecal antibody synthesis speciﬁc for the following re-
spective antigen between V0 and V12 against that for all other
respective antigens: (1) JCV against all other antigens, (2)
BKV, (3) KIV, (4) WUV, (5) measles, (6) rubella, (7) VZV,
(8) mumps, (9) HSV-1, (10) HSV-2, (11) CMV, (12) EBV-
VCA, (13) EBNA-1, (14) inﬂuenza A, (15) inﬂuenza B, (16)
enterovirus, (17) tetanus, (18) diphtheria, (19)H pylori, (20)
C pneumoniae, (21) JCV or BKV, and (22) positive MRZ
reaction. In this exploratory aim, probability values of p <
0.00227 (0.05/22) were considered signiﬁcant according to
Bonferroni correction for multiple comparisons.
Data availability
Anonymized data will be shared upon request by qualiﬁed
investigators.
Results
Changes of total immunoglobulin levels in
serum and CSF during NAT therapy
We ﬁrst analyzed total IgG, IgM, and IgA levels in serum
(ﬁgure 1, A–C) and CSF (ﬁgure 1, D–F) and intrathecal
production of total IgG, IgM, and IgA (ﬁgure 1G–L) in 15
patients with RRMS (male/female ratio 1:4; mean age 40.13
years [range 18–53 years]) before (V0) and during NAT
treatment (V12). Total IgG levels in CSF and intrathecal
production of total IgG, as determined by IgG index, de-
creased signiﬁcantly during NAT therapy (ﬁgure 1D, G, and
J). In addition, NAT treatment signiﬁcantly reduced total IgM
levels in serum and CSF, intrathecal production of IgM (IgM
index), and total IgA levels in CSF (ﬁgure 1B, E, F, and H).
However, the prevalence of donors showing intrathecal IgG,
IgM, or IgA production, i.e., IgG index ≥0.7, or local IgM or
IgA production ≥10%, did not change signiﬁcantly during
NAT therapy (ﬁgure 1J–L).
Heterogeneity of intrathecal production of
pathogen-specific antibodies in untreated
patients with MS
To assess the inﬂuence of NAT therapy on antigen-speciﬁc
IgG responses, we analyzed serum and CSF levels, as well as
intrathecal production of antigen-speciﬁc antibodies,
i.e., antigen-speciﬁc CAIantigen, at before treatment (V0; n =
15), after 12 months (V12; n = 15), and after 24 months of
NAT treatment (V24; n = 6: MS01–MS06) using an array of
20 viral and bacterial antigens (ﬁgure 2). The prevalence of
donors seropositive for the respective antigens was compa-
rable with data from the literature and did not change during
NAT therapy (ﬁgure e-1, links.lww.com/NXI/A146). As
expected, the spectrum of antigens recognized by intrathecally
produced IgG varied considerably among therapy-naive
individuals (V0, ﬁgures 2 and 3A). Before NAT therapy, in-
trathecal production of antibodies against ≥1 antigen was
detectable in 86.7% of donors, against ≥2 antigens in 80.0% of
donors (ﬁgures 2 and 3B). No intrathecal production of
antibodies reactive to any of the 20 antigens tested was ob-
served in 2 donors (13.3%,MS06 andMS15 at V0 in ﬁgure 2),
whereas intrathecal production of antibodies against 10
antigens was found in 2 other donors (MS01 and MS07 at V0
in ﬁgure 2). The antigens most frequently recognized by in-
trathecally produced antibodies were measles (73.3% of
donors), rubella (60.0%), and VZV (53.3%), followed by
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inﬂuenza B virus (46.7%) and C pneumoniae (40.0%) (ﬁgure
3A). MRZ reaction, deﬁned as polyclonal intrathecal antibody
reactivity to ≥2 of the 3 antigens measles (M), rubella (R), and
zoster (Z), was positive in 73.3% (ﬁgure 3B), consistent with
the proportion reported in the literature.10,21 Intrathecal
synthesis of antibodies against mumps virus (33.3%), tetanus
toxoid (33.3%), inﬂuenza A virus (26.7%), HSV-1 (20.0%),
HSV-2 (6.7%), CMV (6.7%), and enterovirus (6.7%) was less
frequent. No intrathecal synthesis of antibodies reactive
against EBV-VCA, EBNA-1, diphtheria toxoid, orHpyloriwas
detectable (ﬁgures 2 and 3A). Of interest, intrathecal antibody
synthesis to the polyomaviruses, KIV (26.7%), JCV (20.0%),
BKV (20.0%), and WUV (13.3%), was detected in some
therapy-naive patients.
Figure 1 Total IgG, IgM, and IgA in the CSF and serum of patients with MS before and during NAT treatment
Changes of absolute levels of total IgG,
IgM, and IgA in serum (A–C) and CSF
(D–F) during NAT therapy are shown.
Changes in intrathecal production of
total IgG, IgM, and IgA are shown by
depicting IgG, IgM, and IgA index (ratio
of CSF/serum antibodies normalized to
ratio CSF/serum albumin) (G–I), as well
as prevalence of patients with signifi-
cant intrathecal synthesis of IgG, IgM, or
IgA (J–L), respectively, as indicated by
IgG index ≥0.7, IgMIF ≥10%, and IgAIF
≥10%, respectively, before (V0) and after
12 months (V12) of NAT treatment (n =
15). The p value is shown in case of
statistically significant differences. Sta-
tistics: Wilcoxon-matched pairs test
(A–I) and McNemar test (J–L). NAT =
natalizumab.
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Changes of intrathecal production of antigen-
specific antibodies during NAT therapy
Only the serum levels of rubella virus–reactive antibodies
decreased signiﬁcantly during NAT therapy, but none of the
ones reactive to all other antigens (ﬁgure e-2 and e-3, links.
lww.com/NXI/A147 and links.lww.com/NXI/A148). In
contrast, NAT therapy reduced CSF levels of antibodies re-
active to JCV, BKV, KIV, WUV, measles virus, rubella virus,
VZV, mumps virus, EBV-VCA, EBNA-1, inﬂuenza A virus,
inﬂuenza B virus, enterovirus, and tetanus toxoid, but not
those reactive to HSV-1, HSV-2, CMV, diphtheria toxoid, H
pylori, andC pneumoniae (ﬁgure 4 and ﬁgure e-2 and e-3, links.
lww.com/NXI/A147 and links.lww.com/NXI/A148).
During NAT therapy, the prevalence of donors producing the
respective antigen-speciﬁc antibodies reduced by 20.0% in
JCV and BKV, respectively, by 13.3% in KIV and inﬂuenza B
virus, respectively, by 6.7% in 6 of 20 antigens, and stayed
unchanged or undetectable in 10 of 20 antigens tested (ﬁgures
2 and 3A). Three donors showed intrathecal production of
antibodies reactive to both JCV and BKV before NAT ther-
apy, and both reactivities were lost in all 3 donors during NAT
treatment, although serum JCV- and BKV-speciﬁc antibody
responses persisted (ﬁgure 4, A and B). In addition, these
donors showed a persistent positive MRZ reaction. No cross-
reactivity between JCV- and BKV-speciﬁc CSF antibodies was
detected at baseline (ﬁgure e-4, links.lww.com/NXI/A149).
Figure 2 Antigen spectrum recognized by intrathecally produced antibodies in patients with MS before and during NAT
treatment.
Antigens are divided into polyomaviral VP1 (PyV: JCV, BKV, KIV, and WUV), viral lysates of the MRZ reaction (measles [M], rubella [R], and VZV [Z]), lysates or
antigens from other neurotropic viruses (mumps, HSV-1, HSV-2, CMV, EBV-VCA, EBNA-1, influenza A, influenza B, and enterovirus), toxoids (tetanus and
diphtheria toxoids), and bacterial antigens (fromnon-neurotropicHpylori and fromneurotropicC pneumoniae). Black indicates intrathecal antibody synthesis
(CAI ≥ 1.5), and white no antigen-specific intrathecal antibody synthesis (CAI < 1.5). Samples with AUs below 5 were considered as not detectable (N).
Longitudinal samples of patients with MS were available from before treatment (V0; n = 15), after 12 months (V12; n = 15), and after 24 months of NAT
treatment (V24; n = 6: only MS01–MS06). Detection of OCBs in the corresponding serum and CSF samples and/or additional bands in CSF is depicted in the
bottom lines. AU = arbitrary unit; CAI = CSF antibody index; EBNA-1 = EBV nuclear antigen-1; EBV = Epstein-Barr virus; EBV-VCA = EBV viral capsid antigen; HSV
= herpes simplex virus; JCV = JC polyomavirus; MRZ =measles, rubella, and zoster antigen; NAT = natalizumab; OCB = oligoclonal band; VZV = varicella zoster
virus.
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Figure 3 Prevalence and loss of intrathecal production of antigen-specific antibodies and OCBs before and during NAT
treatment
(A) Prevalence of patients showing intrathecal production of antibodies to the antigens indicated, before (V0; n = 15, dark gray bars) and after 12 months of
NAT treatment (V12; n = 15, light gray bars). (B) Prevalence of patients with positive MRZ reaction, defined as intrathecal production of antibodies against at
least 2 of the 3MRZ antigens (MRZ virus), before (V0, dark gray bars) and after 12months of NAT treatment (V12, light gray bars) (upper graph) and prevalence
of patientswith intrathecal production of antibodies against at least 2 of the 20 antigens analyzed in (A), before (V0, dark gray bars) and after 12months of NAT
treatment (V12, light gray bars) (lower graph). (C) Frequency of loss of intrathecal production of antibodies (CAI ≥ 1.5) reactive against JCV (black bar,
proportion 3/3) in comparison to the frequency of loss of CAI ≥1.5 specific for all other viral and bacterial antigens tested (white bar, proportion 18/70). (D)
Prevalence of patients with positive OCBs as determined by isoelectric focusing before (V0, dark gray bars) and after 12 months of NAT treatment (V12, light
gray bars). Statistics: McNemar test (A, B, and D) and Fisher exact test for frequency comparisons (C). In the primary aim, the frequency of loss of CAI ≥1.5
reactive against JCVwas comparedwith that specific for all other antigens, and a probability value of p < 0.05was considered significant (C). CAI = CSF antibody
index; MRZ = measles, rubella, and zoster antigen; NAT = natalizumab; OCB = oligoclonal band.
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MRZ reaction did not change signiﬁcantly in all other donors
during NAT therapy (ﬁgure 3B). Intrathecal production of
antibodies against ≥2 antigens persisted in all donors (ﬁgure
3B). Intrathecal antibody production against JCV was sig-
niﬁcantly more frequently lost than the intrathecal production
of antibodies reactive against all other antigens except JCV
Figure 4 JCV-, BKV-, KIV-, andWUV-reactive antibodies in CSFand serumbefore (V0) andafter 12monthsofNAT treatment (V12)
Serum and CSF levels of antibodies reactive to JCV (A), BKV (B), KIV (C), or WUV (D) are depicted in AUs. Intrathecal production of the respective antibodies is
indicated by CSF/serum JCV-, BKV-, KIV-, or WUV-reactive antibody index (CAIJCV, CAIBKV, CAIKIV, and CAIWUV). Dashed lines indicate the value changes in the 3
donors with intrathecal production of JCV- and BKV- specific antibodies at V0 and loss thereof at V12 (each n = 15). Continuous horizontal lines indicate COV of
seropositivity. Dotted horizontal lines indicate the COV for intrathecal antigen-specific antibody synthesis as defined by CAIspec ≥ 1.5). AU = arbitrary unit; CAI
= CSF antibody index; COV = cut-off value; JCV = JC polyomavirus; NAT = natalizumab.
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(primary aim, p = 0.021, ﬁgure 3C). The same was true for the
combination of JCV and BKV (exploratory aim, p = 0.00032)
after Bonferroni correction for multiple comparisons (n =
22), but not for any of the other antigens (ﬁgure e-5, links.
lww.com/NXI/A150).
Changes in OCBs during NAT treatment
OCBs were positive in CSF in 93.3% of donors before and in
80.0% of donors during NAT therapy (ﬁgures 2 and 3D). Loss
of intrathecal OCB production occurred without loss of in-
trathecal production of antigen-speciﬁc antibodies and vice
versa (MS13 vs MS02, MS07, MS11, and MS12 in ﬁgure 2).
OCBs turned positive in 1 patient (MS01) during NAT
therapy, which was not accompanied by occurrence of in-
trathecal production of antigen-speciﬁc antibodies (ﬁgure 2).
Altogether, changes in OCB positivity did not correlate
with changes in intrathecal production of antigen-speciﬁc
antibodies.
Discussion
Here, we report a detailed analysis of the inﬂuence of NAT
therapy on the intrathecal production of antiviral and in
particular anti-JCV antibodies in patients with MS and pos-
sible implications for the development of NAT-PML. Of note,
50%–70% of patients with MS have been reported to be JCV
seropositive.22 Established risk factors for NAT-PML de-
velopment are increased levels of anti-JCV antibodies in se-
rum, duration of NAT treatment longer than 2 years, and
previous long-term immunosuppressive therapies.22 NAT
also induces an elevation of B-cell numbers in the peripheral
blood, which may serve as a cell pool for JCV infection and
dissemination.23,24 NAT-induced upregulation of B-cell
transcription factors may activate early JCV gene expres-
sion, adding to NAT-PML risk.25 Occurrence of PML during
immunomodulatory treatments and in immunodeﬁciencies
that primarily aﬀect B cells indicates the importance of anti-
bodies for controlling JCV.4,26 Recently, we have discovered
viral immune escape mechanisms aﬀecting humoral and
adaptive JCV-speciﬁc immunity.26,27 Patients with MS at
onset of NAT-PML showed reduced CSF antibody responses
against PML-associated JCV variants, which were closed after
immune reconstitution in the CNS for overcoming JCV im-
mune escape.26,28 However, it is not yet well understood why
patients with MS with higher serum anti-JCV antibody levels
are at a higher risk of NAT-PML22 and whether the aﬃnity of
anti-JCV antibodies and/or their ability to recognize and
neutralize multiple JCV variants (including PML-associated
strains) is deﬁcient in these individuals.4,26 It also remains
unclear why NAT therapy is biased to PML and not to any
other infectious CNS disease.
By analyzing antibody reactivities against 20 microbial anti-
gens, we demonstrate high interindividual variability in the
reactivity of intrathecally produced antibodies against various
pathogens in therapy-naive patients withMS.We conﬁrm that
intrathecal production of antibodies against ≥2 viral antigens
is a frequent feature in therapy-naive patients with MS (found
in 80.0%), with MRZ reaction being most prevalent
(73.3%).10,13–15,21 As an interesting novel observation, we
detected intrathecal production of antibodies in therapy-naive
patients with MS against tetanus toxoid (33.3%), JCV
(20.0%), BKV (20.0%), KIV (26.7%), and WUV (13.3%).
This response may be part of theMS-associated “polyspeciﬁc”
CSF antibody response similar to a MRZ-like reaction.10,21
What the role of this broad intrathecal humoral immune re-
sponse in the pathogenesis of MS is and whether it is pro-
tective against viral CNS infections are not clear.
In patients with MS, antibody-producing cells (memory
B cells, plasmablasts, and plasma cells) frequently circulate
between CNS and peripheral blood,29,30 indicating a role of
peripheral humoral immunity in shaping the CNS-resident
B-cell repertoire. The mechanisms establishing the intrathecal
B-cell repertoire are as yet unknown. However, MS-associated
CNS inﬂammation might attract antibody-producing cells by
chemokine cues.31 The probability that B cells producing
antibodies against a speciﬁc pathogen settle to the CNSmight
be inﬂuenced by the frequency of respective CNS homing
antibody-producing cells in peripheral blood and their sto-
chastic migration into the CNS. Additional factors may be
expression of molecules that are needed for CNS entry and
bystander signals for survival.
Of interest, simultaneous intrathecal JCV- and BKV-speciﬁc
antibody production was found in 20% of patients before
NAT therapy, but disappeared during NAT therapy in all of
these patients with MS, whereas anti-JCV and -BKV serum
antibodies andMRZ reaction and CSFOCBs persisted. Initial
reports suggested disappearance of OCBs during NAT ther-
apy in 55%–67% of patients,9 but our data support the per-
sistence of OCBs during NAT therapy and corroborates more
recent reports about less prominent changes in OCB preva-
lence found in 0%–16% of NAT-treated patients.7,8 Meth-
odological diﬀerences in OCB detection between the CSF
laboratories and diﬀerences inMS populations analyzed in the
respective studies could account for the discrepant OCB
ﬁndings seen. Importantly, JCV- and BKV-speciﬁc antibody
responses were signiﬁcantly more frequently lost than in-
trathecal antibody reactivities against other neurotropic
viruses and infectious agents, suggesting an antigen-selective
loss. BKV shares the highest sequence identity with JCV
among human polyomaviruses, and BKV-speciﬁc antibodies
from healthy donors show frequent cross-reactivity against
JCV.26 However, BKV causes nephropathy in up to 10% of
kidney transplant recipients and is not considered to be as-
sociated with PML, MS, or brain disease.
Diﬀerential CNS-migratory properties or requirement of
survival factors for JCV- or BKV-speciﬁc antibody-producing
cells might account for this selective loss. Very Late Antigen
(VLA-4) expression allows antibody-producing cells to cross
the blood-brain barrier (BBB).32,33 Not only VLA-4
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expression levels but also the degree of ligand aﬃnity of VLA-
4, which may be modulated by the activation state of the cell,
determine adhesion and migratory abilities.34,35 Lower ex-
pression or ligand aﬃnity of VLA-4 could be an important
factor to hinder JCV- and BKV-speciﬁc antibody-producing
cells more eﬃciently from crossing the BBB during NAT
therapy than other pathogen-speciﬁc B cells.
On CNS entry, plasmablasts that occupy survival niches suc-
cessfully diﬀerentiate into long-lived plasma cells and become
immobile.31 In contrast, antibody-producing cells lacking survival
cues might eventually undergo apoptosis, and intrathecal anti-
body secretion might depend on continuous CNS inﬁltration of
peripheral cells. We consider this scenario rather unlikely in the
context of JCV- and BKV-speciﬁc B cells because the here
detected absence of cross-reactivity between JCV- and BKV-
speciﬁc antibodies in the CNS, which is usually found in sera of
healthy donors and patients with MS,26 may indicate aﬃnity
maturation of CNS homing, initially cross-reactive B cells to JCV-
monospeciﬁc and BKV-monospeciﬁc cells. Alternatively, in-
trathecal JCV- and BKV-speciﬁc antibody-producing cells might
be more dependent on CD4+ T-cell help for survival and mat-
uration to long-lived plasma cells than B cells speciﬁc for other
pathogens. Again, NATmay inhibit CNS entry of antiviral CD4+
T cells diﬀerentially depending on peripheral precursor fre-
quencies, expression levels of VLA-4, and migratory abilities.6,34
Whereas 20% of therapy-naive patients with MS show in-
trathecal JCV- and BKV-speciﬁc antibody production, NAT
therapy appears to abrogate these immune reactions preferen-
tially compared with responses against other neurotropic viruses.
The observations of this study not only show the previously
known interindividual heterogeneity of the intrathecal poly-
speciﬁc antiviral humoral immune reactions in patients with MS
but also indicate intraindividual heterogeneity in the persistence
of intrathecal antigen-speciﬁc antibody reactivities with some
being more stable and persistent (e.g., MRZ reaction) than
others (intrathecal JCV-speciﬁc antibody synthesis). Assuming
that intrathecally produced anti-JCV antibodies are protective,
their loss during NAT treatment could result in higher risk for
PML development. Limitations of our study are the small cohort
size and short observation period, respectively. Larger studies are
needed to deﬁne how NAT-induced loss of intrathecal JCV-
speciﬁc antibody production inﬂuences PML risk.
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